Multiple Endocrine Neoplasia
13
4
4
6
Key Insights
Highlights
Success Rate
86% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 49/100
7.7%
1 terminated out of 13 trials
85.7%
-0.8% vs benchmark
8%
1 trials in Phase 3/4
50%
3 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (13)
Institutional Registry of Rare Diseases
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
The Registry of Oncology Outcomes Associated with Testing and Treatment
A Retrospective Study for Multiple Endocrine Neoplasia
Studies of Inherited Diseases of Metabolism
Studies of Elevated Parathyroid Activity
Psychosocial Aspects of Multiple Endocrine Neoplasia (MEN) Syndromes
Variables That Are Correlated to Developing Multiple Endocrine Neoplasia (MEN) and Pancreatic Neuroendocrine Tumors (PNET)
Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
Study and Follow-up of Multiple Endocrine Neoplasia Type 1
A Phase II Study of Pertuzumab and Erlotinib for Metastatic or Unresectable Neuroendocrine Tumors
Treatment of Zollinger-Ellison Syndrome With Prevacid
High Dose Somatostatin Analogues in Neuroendocrine Tumors